Substantial evidences suggest that reactive oxygen species participate in the normal aging process and in cancer and neurodegenerative age-related diseases. Parkinson's disease (PD), one of the most common oxidative stress-associated pathology in aging people, is treated with a standard pharmacological protocol consisting in a combined therapy L-dopa plus an inhibitor of dopa-decarboxylase, such as carbidopa. The therapy is well validated for the ability to restoring dopaminergic neurotransmission in PD patients, while L-dopa and carbidopa ability in modulating oxidative stress is currently under discussion. Our aim was to evaluate the impact of L-dopa and carbidopa on several biomarkers of exogenously-induced oxidative stress to validate the overall antioxidant effectiveness of the therapy. For this purpose we used peripheral blood lymphocytes from healthy donors treated in vitro with L-dopa and carbidopa and then challenged by different concentrations of H2O2. Glutathione (GSH, GSSG, GSH/GSSG), malondialdehyde (TBARs), protein carbonyls as well as DNA damage (8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and micronuclei (MN)), modulation was evaluated. Our results show that L-dopa, but not carbidopa, decreases the markers of lipid and protein oxidation and increases the total content of glutathione. Both L-dopa and carbidopa (alone or in combination) are able to counteract the formation of 8-oxodG and to reduce H2O2-induced micronuclei. © 2017 Elsevier Ltd

A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy

Testa, A.
2018

Abstract

Substantial evidences suggest that reactive oxygen species participate in the normal aging process and in cancer and neurodegenerative age-related diseases. Parkinson's disease (PD), one of the most common oxidative stress-associated pathology in aging people, is treated with a standard pharmacological protocol consisting in a combined therapy L-dopa plus an inhibitor of dopa-decarboxylase, such as carbidopa. The therapy is well validated for the ability to restoring dopaminergic neurotransmission in PD patients, while L-dopa and carbidopa ability in modulating oxidative stress is currently under discussion. Our aim was to evaluate the impact of L-dopa and carbidopa on several biomarkers of exogenously-induced oxidative stress to validate the overall antioxidant effectiveness of the therapy. For this purpose we used peripheral blood lymphocytes from healthy donors treated in vitro with L-dopa and carbidopa and then challenged by different concentrations of H2O2. Glutathione (GSH, GSSG, GSH/GSSG), malondialdehyde (TBARs), protein carbonyls as well as DNA damage (8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and micronuclei (MN)), modulation was evaluated. Our results show that L-dopa, but not carbidopa, decreases the markers of lipid and protein oxidation and increases the total content of glutathione. Both L-dopa and carbidopa (alone or in combination) are able to counteract the formation of 8-oxodG and to reduce H2O2-induced micronuclei. © 2017 Elsevier Ltd
Oxidative stress;Carbidopa;Glutathione;DNA damage;L-Dopa;Lipid/protein oxidation markers
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.12079/1606
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
social impact